This is intended for HCPs practising in Great Britain (England, Scotland, Wales) only.

Prescribing Information for SARCLISA®(isatuximab) can be found via the Product Card at the bottom of the page.

In this video, you'll learn about

A case study presented by Dr Clark of a 72 year old RRMM patient who rapidly progressed through 3 lines of treatment in 5 years and experienced severe bone disease complications. The patient had concerns about 4th line treatment however received SARCLISA®+ Pd at 4th Line.

Overview of SARCLISA®

Find out more about SARCLISA® + Pd efficacy and safety data and dosing information.

Dosing and Administration Guide

Download a handy guide to SARCLISA dosing and administration information.

Patient Booklet

Download SARCLISA® patient information.

Get in touch with the Oncology Team

Relapsed Refractory Multiple Myeloma Product


Prescribing Information GB


MAT-XU-2202578 (v2.0)
Date of preparation: August 2023

MAT-XU-2202571 (v1.0)
Date of Preparation: September 2023 

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.